ReviewJournal of clinical medicine2024
Advancing Cardiac Amyloidosis Care Through Insights from Cardiopulmonary Exercise Testing.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Efficacy and Safety of Cardiopulmonary Exercise Testing in Advanced Heart Failure Receiving Intravenous Inotropes.Journal of cardiovascular development and disease · 2026Article
- Small Hearts, Big Clues: A Narrative Review on Sex-Related Disparities in the Diagnosis and Management of Cardiac Amyloidosis in Women.Journal of clinical medicine · 2026Review
- The Current Role of Physiotherapy in Systemic Light-Chain (AL) Amyloidosis and Multiple Myeloma.Life (Basel, Switzerland) · 2026Review
- Better Outcomes After Initiation of Disease-Modifying Therapy in Patients with Transthyretin Cardiac Amyloidosis.Journal of clinical medicine · 2026Article
- Cardiopulmonary Exercise Testing and HFpEF: Diagnostic and Therapeutic Perspectives.Healthcare (Basel, Switzerland) · 2025Review
- Functional Capacity Evaluation and Rehabilitation Strategies in Cardiac Amyloidosis: A Comprehensive Review.Journal of clinical medicine · 2025Review
- Early Phase I Cardiac Rehabilitation Integrated with Multidisciplinary Post-Acute Care in Decompensated Heart Failure: Insights from Serial Cardiopulmonary Exercise Testing.Medicina (Kaunas, Lithuania) · 2025Article
- Multimodality Imaging Leading the Way to a Prompt Diagnosis and Management of Transthyretin Amyloidosis.Journal of clinical medicine · 2025Article
- Cardiopulmonary Exercise Testing Correlates with Quantitative Left Ventricular [Journal of clinical medicine · 2025Article
- Transthyretin Amyloid Cardiomyopathy: Current Diagnostic Approach and Risk Stratification with Multimodality Imaging.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis, encompassing both transthyretin (ATTR) and light-chain (AL) types, poses considerable challenges in patient management due to its intricate pathophysiology and progressive course. This narrative review elucidates the pivotal role of cardiopulmonary exercise testing (CPET) in the assessment of these patients. CPET is essential for evaluating disease progression by measuring cardio-respiratory performance and providing prognostic insights. This functional test is crucial not only for tracking the disease trajectory, but also for assessing the effectiveness of disease-modifying therapies. Moreover, CPET facilitates the customization of therapeutic strategies based on individual patient performance, enhancing personalized care. By objectively measuring parameters such as peak oxygen uptake (VO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.